Results support the potential of PMN310 to improve outcomes by selectively targeting oligomers and avoiding binding to monomer and plaque ...
Results support the potential of PMN310 to improve outcomes by selectively targeting oligomers and avoiding binding to monomer and plaque ...
Newton Biocapital enters as new investor, strong participation of existing investorsPivotal Phase 2b trial initiation in 2027 of BIOX-101 to...
Newton Biocapital enters as new investor, strong participation of existing investorsPivotal Phase 2b trial initiation in 2027 of BIOX-101 to...
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of...
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of...
NEW YORK, Dec. 9, 2025 /PRNewswire/ -- BestQool is now giving a holiday offer to help people smoothly move into...
With Human Studies On Every Formula, Qualia's Industry-Leading Research Standards Are Fueling Innovation and Rapid GrowthCARLSBAD, Calif., Dec. 9, 2025...
Annual awards recognize industry's most successful campaigns, initiatives, people, and teamsBALTIMORE, Dec. 9, 2025 /PRNewswire/ -- Sage Growth Partners (Sage), a...
Introduced brain-imaging analysis products, including Neurophet AQUA AD, which enables monitoring of adverse effects related to Alzheimer's disease treatmentsHighlighted clinical...
Findings support advancement into Phase 2 to explore a first-in-class pathway aimed at stress-related neuropsychiatric conditions NEW YORK CITY, NEW...
NEW YORK, Dec. 8, 2025 /PRNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) today announced the initiation of...
DELRAY BEACH, Fla., Dec. 8, 2025 /PRNewswire/ -- According to MarketsandMarkets™, the Clinical Communication & Collaboration Market is projected to grow...
Lingo, Abbott's first over-the-counter biowearable, expands to Android devicesContinuous glucose monitoring devices help people maintain healthy glucose levels, which are...
In addition, the expansive elacestrant clinical development program updates reinforce its potential as a backbone endocrine therapy in combination settings,...
Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression...
Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR (by BICR-RANO), including in patients with active...
Demonstrated brain imaging analysis solutions, including 'Neurophet AQUA AD,' which enables monitoring of adverse effects associated with Alzheimer's disease treatmentsHighlighted...
A roundup of the most newsworthy healthcare press releases from PR Newswire, including new company mergers, Alzheimer's fundraising and advances...
BOSTON, Dec. 05, 2025 (GLOBE NEWSWIRE) -- A recent setback due to unexpected safety concern from a phase 2 study...